Kikuchi-Fujimoto Disease, A Possible Complication of Rituximab Treatment.
- Author:
Jiwon LEE
1
;
Hye Jin CHANG
;
Sang Taek LEE
;
Hee Gyung KANG
;
Il Soo HA
;
Hae Il CHEONG
Author Information
1. Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea. cheonghi@snu.ac.kr
- Publication Type:Case Report
- Keywords:
B-cell;
Kikuchi-Fujimoto disease;
Nephrotic syndrome;
Rituximab
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
B-Lymphocytes;
Child;
Histiocytic Necrotizing Lymphadenitis;
Humans;
Immunoglobulin G;
Lymphadenitis;
Nephrotic Syndrome;
Rituximab
- From:Journal of the Korean Society of Pediatric Nephrology
2012;16(2):138-141
- CountryRepublic of Korea
- Language:English
-
Abstract:
Rituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, has been used as a rescue therapy for steroid-dependent or refractory nephrotic syndrome. However, the adverse effects of rituximab are yet to be investigated. We report a case of a 9-year-old boy with steroid-dependent nephrotic syndrome who developed Kikuchi-Fujimoto disease after several cycles of rituximab therapy. Kikuchi-Fujimoto disease is a benign, self-limited necrotizing histiocytic lymphadenitis of unknown etiology. In the present case, Kikuchi-Fujimoto disease developed when the peripheral blood B-cell count of the patient was at nadir, and the lesion regressed slowly but spontaneously after recovery of the B-cell count. To our knowledge, although the pathologic diagnosis of Kikuchi-Fujimoto disease was unavailable, this is the first report of Kikuchi-Fujimoto disease with clinical diagnosis as a possible adverse effect of rituximab.
